235 related articles for article (PubMed ID: 20637220)
1. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases.
Tremblay JM; Kuo CL; Abeijon C; Sepulveda J; Oyler G; Hu X; Jin MM; Shoemaker CB
Toxicon; 2010 Nov; 56(6):990-8. PubMed ID: 20637220
[TBL] [Abstract][Full Text] [Related]
2. Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function.
Tremblay JM; Vazquez-Cintron E; Lam KH; Mukherjee J; Bedenice D; Ondeck CA; Conroy MT; Bodt SML; Winner BM; Webb RP; Ichtchenko K; Jin R; McNutt PM; Shoemaker CB
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987745
[TBL] [Abstract][Full Text] [Related]
3. Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies.
Lam KH; Tremblay JM; Perry K; Ichtchenko K; Shoemaker CB; Jin R
PLoS Pathog; 2022 Jan; 18(1):e1010169. PubMed ID: 34990480
[TBL] [Abstract][Full Text] [Related]
4. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region.
Dong J; Thompson AA; Fan Y; Lou J; Conrad F; Ho M; Pires-Alves M; Wilson BA; Stevens RC; Marks JD
J Mol Biol; 2010 Apr; 397(4):1106-18. PubMed ID: 20138889
[TBL] [Abstract][Full Text] [Related]
5. Single-Domain Antibody Multimers for Detection of Botulinum Neurotoxin Serotypes C, D, and Their Mosaics in Endopep-MS.
Harmsen MM; Cornelissen JC; van der Wal FJ; Bergervoet JHW; Koene M
Toxins (Basel); 2023 Sep; 15(9):. PubMed ID: 37755999
[TBL] [Abstract][Full Text] [Related]
6. Two VHH Antibodies Neutralize Botulinum Neurotoxin E1 by Blocking Its Membrane Translocation in Host Cells.
Lam KH; Perry K; Shoemaker CB; Jin R
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32992561
[TBL] [Abstract][Full Text] [Related]
7. Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling.
Kumar G; Kumaran D; Ahmed SA; Swaminathan S
Acta Crystallogr D Biol Crystallogr; 2012 May; 68(Pt 5):511-20. PubMed ID: 22525749
[TBL] [Abstract][Full Text] [Related]
8. Progress in cell based assays for botulinum neurotoxin detection.
Pellett S
Curr Top Microbiol Immunol; 2013; 364():257-85. PubMed ID: 23239357
[TBL] [Abstract][Full Text] [Related]
9. Algal chloroplast produced camelid VH H antitoxins are capable of neutralizing botulinum neurotoxin.
Barrera DJ; Rosenberg JN; Chiu JG; Chang YN; Debatis M; Ngoi SM; Chang JT; Shoemaker CB; Oyler GA; Mayfield SP
Plant Biotechnol J; 2015 Jan; 13(1):117-24. PubMed ID: 25229405
[TBL] [Abstract][Full Text] [Related]
10. Botulinum neurotoxins and botulism: a novel therapeutic approach.
Thanongsaksrikul J; Chaicumpa W
Toxins (Basel); 2011 May; 3(5):469-88. PubMed ID: 22069720
[TBL] [Abstract][Full Text] [Related]
11. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
12. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
13. Facile electrochemical detection of botulinum neurotoxin type E using a two-step proteolytic cleavage.
Park S; Shin YM; Song JJ; Yang H
Biosens Bioelectron; 2015 Oct; 72():211-7. PubMed ID: 25982730
[TBL] [Abstract][Full Text] [Related]
14. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
[TBL] [Abstract][Full Text] [Related]
15. Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination.
Kuo CL; Oyler GA; Shoemaker CB
PLoS One; 2011; 6(5):e20352. PubMed ID: 21629663
[TBL] [Abstract][Full Text] [Related]
16. Llama-derived single-domain antibodies for the detection of botulinum A neurotoxin.
Swain MD; Anderson GP; Zabetakis D; Bernstein RD; Liu JL; Sherwood LJ; Hayhurst A; Goldman ER
Anal Bioanal Chem; 2010 Sep; 398(1):339-48. PubMed ID: 20582697
[TBL] [Abstract][Full Text] [Related]
17. The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies.
Rasetti-Escargueil C; Avril A; Miethe S; Mazuet C; Derman Y; Selby K; Thullier P; Pelat T; Urbain R; Fontayne A; Korkeala H; Sesardic D; Hust M; Popoff MR
Toxins (Basel); 2017 Oct; 9(10):. PubMed ID: 28974033
[TBL] [Abstract][Full Text] [Related]
18. Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain.
Wang HH; Riding S; Lindo P; Singh BR
Appl Environ Microbiol; 2010 Oct; 76(19):6658-63. PubMed ID: 20693440
[TBL] [Abstract][Full Text] [Related]
19. Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.
Mukamoto M; Maeda H; Kohda T; Nozaki C; Takahashi M; Kozaki S
Jpn J Infect Dis; 2013; 66(1):46-50. PubMed ID: 23429085
[TBL] [Abstract][Full Text] [Related]
20. Development and Characterization of Monoclonal Antibodies to Botulinum Neurotoxin Type E.
Bever CS; Scotcher M; Cheng LW; Hnasko RM; Stanker LH
Toxins (Basel); 2019 Jul; 11(7):. PubMed ID: 31337022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
